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Key components of the miRNA-mediated gene regulation pathway are localized in cytoplasmic processing bodies
(P-bodies). Mounting evidence suggests that the presence of microscopic P-bodies are not always required for miRNA-
mediated gene regulation. Here we have shown that geldanamycin, a well-characterized HSP90 inhibitor, abolishes
P-bodies and significantly reduces Argonaute and GW182 protein levels but does not affect the miRNA level and the
efficiency of miRNA-mediated gene repression; however, it significantly impairs siRNA loading and the efficacy of
exogenous siRNA. Our data suggests that HSP90 protein chaperones Argonautes before binding RNA and may facilitate
efficient loading of small RNA.
INTRODUCTION
Small regulatory RNAs such as small interfering RNAs (siRNAs)
and micro RNAs (miRNAs) regulate gene expression mainly
at the posttranscriptional level in eukaryotes. Argonautes,
small RNAs, and miRNA-targeted mRNAs have all been
shown to be localized in cytoplasmic processing bodies (P-
bodies; Ding et al., 2005; Jakymiw et al., 2005; Liu et al., 2005a;
Pillai et al., 2005; Sen and Blau, 2005; Bhattacharyya et al.,
2006). This cytoplasmic structure is involved in various mRNA
decay mechanisms including poly(A)-dependent decapping,
AU-rich element–mediated mRNA destabilization, and non-
sense-mediated mRNA degradation (NMD; Jakymiw et al.,
2007; Eulalio et al., 2007a).
Metazoan Argonautes interact with the GW182 protein
family, which were first identified as a P-body marker (Ey-
stathioy et al., 2002; Ding et al., 2005; Liu et al., 2005a; Meister
et al., 2005; Rehwinkel et al., 2005; Landthaler et al., 2008).
Depletion of the GW182 family abolishes visible P-bodies;
this also leads to a loss of miRNA-mediated repression in
reporter constructs because the Argonautes’ interaction with
GW182 is required for miRNA-mediated gene repression
(Liu et al., 2005a; Meister et al., 2005; Behm-Ansmant et al.,
2006; Eulalio et al., 2008, 2009; Lian et al., 2009). Many studies
have shown that the function of GW182 proteins in transla-
tional repression can be uncoupled from Argonautes, sug-
gesting that miRNA-loaded Argonautes recruit GW182 pro-
teins to the targeted mRNA (Li et al., 2008; Chekulaeva et al.,
2009; Lazzaretti et al., 2009; Lian et al., 2009; Zipprich et al.,
2009). Other proteins, such as Mov10 and RCK/p54 that
interact with Argonautes and have an essential role in
miRNA-mediated gene repression also colocalize with Ar-
gonautes in the P-bodies (Meister et al., 2005; Chu, 2006).
Depletion of RCK/p54 also disrupts the formation of visible
P-bodies (Chu and Rana, 2006).
The presence of microscopic P-bodies does not seem to be
a prerequisite for miRNA-mediated gene repression. For
instance, depletion of Lsm1, a P-body component, disrupts
P-body formation in mammalian cells but does not signifi-
cantly affect miRNA-mediated gene repression (Chu, 2006).
It has also been suggested that P-body formation is the
consequence of RNA silencing (Eulalio et al., 2007b). In addi-
tion, recent studies have shown that GW182 function can be
uncoupled from its localization in P-bodies (Eulalio et al., 2009).
Interestingly, formation of P-bodies requires the presence
of small regulatory RNAs. Depletion of Drosha leads to the
loss of visible P-bodies that could be reconstituted by the
introduction of synthetic siRNAs (Pauley et al., 2006). Intro-
duction of functional siRNAs into mammalian cells induce
up-regulation of Ago2 and GW182 and produce more micro-
scopic P-bodies (Lian et al., 2007; Jagannath and Wood, 2009).
Biochemical purifications revealed that Argonaute pro-
teins frequently copurify with heat shock proteins (Hock et
al., 2007; Landthaler et al., 2008). It was shown that heat
shock protein 90 (HSP90) binds directly to the N-terminus of
overexpressed mammalian Ago2 and was proposed to be
required for stabilizing Dicer interactions with Ago2 (Tah-
baz et al., 2001, 2004). However, very recently a study sug-
gested that HSP90 function is required for RISC function
(Pare et al., 2009), and genetic studies in Arabidopsis revealed
that a known binding partner of HSP90, Cyclophilin 40, is
required for miRNA activity (Smith et al., 2009). HSP90 is
part of a multiprotein chaperone complex that is dependent
on ATP activity. Unlike other molecular chaperones, HSP90
seems to only act upon a specific subset of about 200 pro-
teins (Picard, 2002). The majority of the set are made up of
signaling proteins, cell cycle regulators, and apoptotic fac-
tors (Workman et al., 2007). HSP90 may regulate the function
or turnover of its client proteins. In the presence of HSP90
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inhibitors, such as geldanamycin, which mimics ATP bind-
ing (Smith et al., 1995), the client proteins become unstable
and are quickly degraded. Because of the vast majority of
HSP90 client proteins being mutated in cancer, HSP90 is a
promising drug target. Geldanamycin analogues such as
17AAG [17-(allylamino)-17-demethoxygeldanamycin] are
currently in clinical trials (Banerji et al., 2005).
In this study, we have found that visible P-bodies were
abolished when cells were treated with geldanamycin or
17AAG. HSP90 inhibitors were shown to significantly re-
duce the levels of human Argonautes and GW182 proteins.
Our data also indicates that loss of P-bodies and the
geldanamycin-dependent decrease in expression of key
components of the miRNA regulatory pathway did not re-
sult in alteration of miRNA level or miRNA-mediated gene
repression. However, the efficacy of exogenous siRNAs was
significantly reduced. Therefore, we propose that geldana-
mycin inhibits programming of RISC by facilitating the de-
pletion of Argonautes that are not bound to small RNAs.
MATERIALS AND METHODS
Reagents
The following HSP90 inhibitors were used: 10 mM stock solutions of geldana-
mycin and 17AAG (LC Laboratories, Woburn, MA) were dissolved in dimeth-
ylsulfoxide and stored at 80°C. MG132 (Calbiochem, La Jolla, CA) was
dissolved in dimethylsulfoxide (DMSO, Sigma-Aldrich, Dorset, United
Kingdom).
Antibodies
Antibodies and dilutions used for Western blotting were as follows:
monoclonal mouse anti--tubulin (Sigma-Aldrich), 1:10,000; monoclonal
mouse anti--actin (Oncogene Research Products, Boston, MA), 1:250,000;
mouse anti-Dicer (Abcam, Cambridge, United Kingdom), 1:250; monoclonal mouse
anti-FLAG (Sigma-Aldrich), 1:1000 and 1:100 for immunofluorescence; rat
monoclonal anti-Ago2 (11A9; Rudel et al., 2008), 1:100; rat monoclonal to Ago1
(Rudel et al., 2008), 1:50; rabbit polyclonal anti-drosha (Abcam), 1:1000; mono-
clonal mouse anti-HSP90 (Assay Designs, Ann Arbor, MI), 1:6000; monoclonal
rabbit anti-Ras (Abcam), 1:50,000; human anti-GW182 (gift from Marvin J.
Fritzler, University of Calgary), 1:2000 and 1:5000 for immunofluorescence;
HRP-conjugated goat anti-mouse IgG, 1:10,000; HRP-conjugated donkey anti-
rabbit IgG, 1:10,000; HRP-conjugated donkey anti-rat IgG, 1:10,000; HRP-
conjugated donkey anti-Human IgG, 1:10,000; FITC-conjugated goat anti-
mouse IgG, 1:100; and FITC-conjugated goat anti-Human IgG, 1:100 (all from
Jackson ImmunoResearch, West Grove, PA).
Oligonucleotides
The following oligonucleotides were used: RNA oligonucleotides (MWG
Eurofins, Ebersberg, Germany) for Northern hybridization to detect mir-21
(5-UCAACAUCAGUCUGAUAAGCUA-3) and to detect let-7 (5-UAUA-
CAACC UACUACCUCAUU-3); DNA oligonucleotides (Sigma) for North-
ern hybridization to detect U6: U6-fwd (5-GGAACGATACAGAGAAGAT-
TAGCATGGCCCCTGCGCAAGG-3) and U6-rev (5-CCTTGCGCAG-3);
siRNAs (MWG) to knock down pGL3: sense 5-CUUACGCUGAGUACUUC-
GAdTdT-3; nontargeting siRNA duplex (MWG): sense 5-AGGUAGUGU-
AAUCGCCUUGdTdT-3; 2-O-methyl oligonucleotides (Dharmacon, Boul-
der, CO): let-7 complementary (5-Bio-UCUUCACUAUACAACCU CUA
CCU CAACCUU-3) and control 2-O-Methyl-oligonucleotide (5-Bio-CAU-
CACGUACGCGGAAUCUUCGAAAUGUC-3).
Plasmids
pRL-TK, pGL2, and pGL3 (Invitrogen, Paisley, United Kingdom) and psi-
CHECK2-let-7X8 and psiCHECK2-let-7X0 (Iwasaki et al., 2009; gifts from
Yukihide Tomari, University of Tokyo) were used in this study. Reporters
that contain the 3 untranslated regions (UTRs) of nRAS and kRAS were
pGL3-NRASlong and PGL3-KRAS (Johnson et al., 2005). To produce let-7X3
(renilla luciferase that contains three perfect complementary let-7a sites) an
oligo containing three target sites for human let-7a (5-GTTGCGGCCG-
CTGAGGTAGTAGGTTGTATAGTTTCGACTGAGGTAGTAGGTTGTATAG-
TTTCGACTGAGGTAGTAGGTTGTATAGTTCTCGAGTTG-3) and let-7X3m
(which carries three point mutations in the let-7a seeds and one at the cleavage
sites) an oligo with mutated target sites (5-GTTGCGGCCGCTGTCCTAG-
TAGCTTGTATAGTTTCGACTGTCCTAGTAGCTTGTATAGTTTCGACTGT-
CCTAGTAGCTTGTATAGTTCTCGAGTTG-3) were made double-stranded
using Klenow’s reagent, digested with NotI and XhoI, and ligated into psi-
Check-2 (Promega, Southampton, United Kingdom) that had been linearized
with the same restriction enzymes. To produce let-7X1 (renilla luciferase
which contains one perfect complementary let-7a sites) oligos containing one
target site for human let7a sense 5-GATCGCTCGAGAACTATACAAC-
CTACTACCTCAGCGGCCGCTG-3 and antisense 5-CAGCGGCCGCTGA-
GGTAGTAGGTTGTATAGTTCTCGAGCGATC-3 were annealed and let-
7X1m (which carries three point mutations in the let-7a seed and one at the
cleavage site) oligos containing mutated target site sense 5 GATCGCTC-
GAGAACTATACAAGCTACTAGGACAGCGGCCGCTG-3 and anti-sense
5-CAGCGGCCGCTGTCCTAGTAGCTTGTATAGTTCTCGAGCGATC-3 were
annealed, digested with NotI and XhoI, and ligated into psiCheck-2 (Promega)
that had been linearized with the same restriction enzymes. For production of
FLAG::Ago2(PAZ10), DNA encoding part of Ago2 that includes the PAZ domain
was obtained by a double restriction digest of Ago2(PAZ10)-Myc (Liu et al.,
2005b) using EcoRV and PasI. This fragment was used to replace the correspond-
ing part of wild-type Ago2 in a pCMV5 vector expressing FLAG-tagged Ago2
(CLS Cloning Service, University of Dundee). pcDNA5 FRT/TO FLAG-1
TNRC6C and pCDNA5 FRT/TO FLAG-1 Ago2 plasmids (CLS Cloning Service,
University of Dundee) were used for generating stable inducible cells.
Cell Culture
HeLa and U2OS cells were maintained at 37°C, 5% CO2, in DMEM (GlutaMax,
Invitrogen, Paisley, United Kingdom) supplemented with 10% FCS and 60
U/ml penicillin and streptomycin. Stably expressing FLAG-Ago2 and FLAG-
TNRC6C HEK-293 Flp-In (T-Rex) cells under the control of a tetracycline
responsive promoter were generated by cotransfecting each plasmid, either
pcDNA5 FRT/TO FLAG-1 Ago2 or pcDNA5 FRT/TO FLAG-1 TNRC6C, with
pOG44 using Lipofectamine 2000 (Invitrogen) according to the manufactur-
er’s instructions, followed by selection with hygromycin B (100 g/ml) and
blasticidin (15 g/ml). After selection cells were cultured in DMEM sup-
plemented with 10% FCS (tetracycline free) and 60 U/ml penicillin and
streptomycin and 100 g/ml Hygromycin B and 15 g/ml blasticidin.
Cells were induced overnight with tetracycline (100 ng/ml).
Transfections
For dual luciferase assays, DMSO or geldanamycin (10 M 16 h) pretreated
HeLa cells were transfected in triplicate with luciferase constructs (0.16 g/
well). Transfections were performed in 24-well plates using Lipofectamine
2000 (Invitrogen) following the manufacturer’s instructions. After 6 h the
media were replaced with full media containing either DMSO or geldanamy-
cin (10 M) for another 16 h.
For transfection and cotransfection with siRNAs, DMSO or geldanamycin
(10 M; 16 h) pretreated HeLa cells were cotransfected in triplicate with
increasing amounts of siRNA against pGL3 and DNA plasmids, pGL3 (0.2
g/well) and pRL-TK (0.1 g/well), using Lipofectamine 2000 (Invitrogen).
Six hours after transfection, the media were replaced with full media contain-
ing either DMSO or geldanamycin (10 M) for another 16 h. Also, HeLa cells
were cotransfected with increasing amounts of siRNA against pGL3 and
either cognate-targeted plasmids pGL3 (1 g/well) and nontargeted pRL-TK
(0.5 g/well) or nontargeted pRL-TK plasmid (1.5 g/well). Transfections
were performed in six-well plates with 10 l of Lipofectamine 2000 (Invitro-
gen). After 6 h, the media were replaced with full media containing either
DMSO or geldanamycin (10 M) for another 16 h.
HeLa cells were cotransfected for 24 h with plasmids expressing either
FLAG::Ago2 (2.5 g) or FLAG::Ago2(PAZ10) (4 g) or Ago2 and siRNA
against pGL3 (10 nM) or FLAG::Ago2(PAZ10) and siRNA against pGL3 (10
nM) with Lipofectamine 2000 (Invitrogen) following the manufacturer’s in-
structions to generate equal expression of the constructs. Transfected cells
were then treated with either DMSO or geldanamycin (10 M; 16 h).
Dual Luciferase Assays
All cells were harvested with 100 l 1 passive lysis buffer (Promega) per
well of a 24-well plate. Luciferase activity was quantified using a dual
luciferase reporter assay system (Promega), and the luminescence was mea-
sured on a Microlumat Plus LB96V microplate luminometer (EG&G Berthold,
Natick, MA).
Cell Lysis, Immunoprecipitation, and Immunoblotting
HeLa cells were treated with either DMSO or geldanamycin for 16 h. Lysates
were prepared by lysing cells in NP40 lysis buffer (50 mM Tris/HCl, pH 7.5,
150 mM sodium chloride, 1% [vol/vol] NP40 (alternative), 10 M DTT, and
one complete protease inhibitor cocktail tablet [Roche, Lewes, East Sussex,
United Kingdom] per 10 ml of buffer). Immunoprecipitation (IP) of Ago2 was
performed using rat monoclonal anti-Ago2 [11A9] for 2 h at 4°C on a carousel
mixer. rec-protein G Sepharose beads (Invitrogen) were washed three times
with 1 ml Tris-buffered saline and 0.1% Tween (TBST) and resuspended in
NP40 lysis buffer and then added to the IPs for an additional hour. Stably
expressing FLAG-Ago2 HEK-293s Flp-In (T-Rex) cells under the control of a
tetracycline-responsive promoter were lysed in NP40 buffer with the addition
of RNAse inhibitor 40 U/ml (New England Biolabs, Hitchin, Herts, United
Kingdom). IP of FLAG-Ago2 was performed using ANTI-FLAG M2 affinity
gel. The bound fractions were washed three times for 5 min with NP40 lysis
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buffer. Ago2-associated proteins were eluted by boiling in SDS loading dye
and were subjected to analysis by SDS-PAGE and Western blotting.
The protein concentrations of cell lysates were determined by BCA assay
(Thermo Scientific, Waltham, MA). Samples in 1 SDS loading dye were
heated to 95°C for 10 min before being resolved in 10% SDS-polyacrylamide
gels and transferred to PVDF membranes (Millipore, Watford, Herts, United
Kingdom). Membranes were blocked in 5% dry milk (wt/vol)/TBST for 30 min,
then incubated with primary antibody diluted in 1 TBS, 2% BSA (wt/vol), 0.1%
Tween-20, and 0.1% NaN3, and incubated with the membrane overnight at 4°C.
HRP-conjugated secondary antibodies diluted in 5% dry milk [wt/vol]/TBST
were incubated with the membrane for 1 h at room temperature. Membranes
were visualized with ECL (Supersignal West Pico Chemiluminescent Substrate
[Thermo Scientific] or Immoblion Western [Millipore]).
RNA Isolation and Northern Blotting
RNA was isolated with Trizol reagent (Invitrogen). Detection of small RNAs
was performed using a sensitive Northern blot method described by Pall et al.
(2007) and were probed with the RNA oligonucleotides described above after
5 end labeling with polynucleotide kinase (New England Biolabs). Hybrid-
ization was done at 37°C overnight, and the blots were washed twice for at
least 1 h at 37°C in 2 SSC, 0.1% (wt/vol) SDS. For U6, a DNA probe was
synthesized from a single-stranded template using Klenow reagent (Strat-
agene, La Jolla, CA) on the oligonucleotides described above in the presence
of labeled dATP. After synthesis, the duplex was denatured at 95°C, and
hybridization and washing were performed at 55°C. Northern membranes
were stripped by boiling for 5 min in 0.1% SDS. Imaging was performed with
FLA-5100 phosphoimager (Fujifilm, Tokyo, Japan) using Fujifilm screens and
visualized and quantified with ImageGauge 4.1 (Fujifilm).
Immobilized 2-O-methyl Oligonucleotide Capture of
miRNA Complexes
Stably expressing FLAG-Ago2 HEK-293s Flp-In (T-Rex) cells under the con-
trol of a tetracycline-responsive promoter were lysed in NP40 buffer with
added RNAse inhibitor (40 U/ml; New England Biolabs) and half of the the
lysate was used to perform the FLAG IP (described above). The remaining
lysate was incubated overnight at 4°C with 2-O-methyl oligonucleotides (100
pmol) that were bound to 25 l of Dynabeads M-270 Magnetic Streptavidin
(Dynal Biotech, Lake Success, NY) per reaction. The bound fraction was
washed with lysis buffer three times, collected with a magnetic stand, and
assayed by Western blotting.
HeLa cells were pretreated with either DMSO or geldanamycin for 16 h.
Cell were lysed in NP40 buffer with added RNAse inhibitor (40 U/ml; New
England Biolabs) and incubated overnight at 4°C with 2-O-methyl oligonu-
cleotides (100 pmol) that were bound to 25 l of Dynabeads M-270 Magnetic
Streptavidin (Dynal Biotech) per reaction. The bound fraction was washed
with lysis buffer three times, collected with a magnetic stand, and assayed by
Western blotting.
Immunofluorescence
Cells were grown on coverslips before treatment as indicated and fixed for 5
min in 4% PFA/PBS. Cells were permeabilized for 10 min with 0.1% Triton
X-100/PBS. Cells were then blocked in 5% normal donkey serum and TBST for
30 min before washing three times for 5 min in TBST. Cells were stained with
primary antibody diluted in blocking solution for 1 h at room temperature before
washing three times for 5 min in TBST and were incubated with secondary
antibodies for a further hour and washed three times for 5 min in TBST. Cells
were then stained with 0.1 mg/ml DAPI and mounted for imaging with Vectash-
ield mounting medium (Vector Laboratories, Peterborough, United Kingdom).
Images were collected using a Deltavision DV3 widefield microscope and pro-
cessed using Softworx (Applied Precision, Issaquah, WA) and OME software.
Images are presented as maximal intensity projections.
Quantification of Western Blots and Northern Blots
Densitometery quantification was performed using ImageGuage (Fujifilm).
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Figure 1. Geldanamycin treatments disperse micro-
scopic P-bodies and decrease the level of Argonautes
and GW182 proteins. (A and B) Geldanamycin de-
creases the size and number of P-bodies in human cells.
HeLa (A) and T-Rex 293 (B) cells were treated with
geldanamycin (7 M for 16 h), and P-bodies were visu-
alized with immunostaining for endogenous GW182 (A)
or overexpressed FLAG-tagged TNRC6C (B). DAPI stain-
ing was used to visualize cell nuclei. (C) Geldanamycin
dampens endogenous Argonautes and GW182 expres-
sion. HeLa cells were treated with geldanamycin (10 M
for 16 h), and the expression level of proteins involved in
the miRNA pathway as well as the let-7 target Ras were
followed by Western blotting. -Actin was used as a load-
ing control. The numbers on the top of each panel indicate
the relative abundance of the respective proteins. (D)
Overexpressed Ago2 and TNRC6C are sensitive to HSP90
inhibition. 293 T-Rex cells stably expressing tetracycline-
inducible (Tet) FLAG-tagged hAgo2, and FLAG-tagged
TNRC6C were treated with geldanamycin (GD; 10 M for
16 h), and the expressions of the transgenes were followed
by Western blot using a FLAG antibody. The efficiencies of
the geldanamycin treatments were confirmed by Western
blotting of endogenous hAgo2. -Tubulin was used as the
loading control. The numbers on the top of each panel
indicate the relative abundance of the respective proteins.
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RESULTS
Geldanamycin Decreases the Levels of Mammalian
Argonaute and GW182 Proteins
By testing several factors that may influence the microscopic
appearance of diverse cytoplasmic and nuclear structures, we
have found that geldanamycin, a potent inhibitor of HSP90,
significantly decreases the number of visible P-bodies in mam-
malian cells. Immunofluorescence studies showed that in the
presence of geldanamycin, the P-body marker GW182 became
dispersed, and the number and size of visible P-bodies were
decreased compared with the mock-treated cells (Figure 1A).
Similar results were obtained when we followed the expression
and localization of cells that stably expressed FLAG-tagged
TNRC6C, under the control of a tetracycline-responsive pro-
moter (Figure 1, B and D). It has been shown that geldanamy-
cin dampens the expression of mammalian Ago2 in vitro (Tah-
baz et al., 2001); however, the depletion of Ago2 does not
significantly alter the phenotype of visible P-bodies (Lian et al.,
2007; Jagannath and Wood, 2009). Therefore we tested the
expression levels of key components of the miRNA pathway,
and we confirmed that endogenous and overexpressed Ago2
and endogenous Ago1 were sensitive to geldanamycin (Fig-
ures 1, C and D, and 2A) and 17AAG (Supplementary Figure
1A). Overexpressed human Ago3 also failed to accumulate in
HeLa cells treated with geldanamycin (Supplementary Figure
1B). In addition, we have shown that the expression of endog-
enous GW182 and stably overexpressed TNRC6C also de-
creased after geldanamycin treatment (Figures 1, C and D, and
2A). In contrast Drosha and Dicer, two key components of
miRNA maturation, did not seem to respond to geldanamycin
treatment (Figure 1C). We could alleviate the effects of geldana-
mycin upon Ago1 and Ago2 by the addition of the proteasome
inhibitor MG132, suggesting that HSP90 is required for pro-
tecting Ago1 and Ago2 from degradation by the proteasome
(Supplementary Figure 1C).
Geldanamycin Treatment Does Not Affect
miRNA-mediated Gene Regulation
Interestingly, when we examined the miRNA levels in the
geldanamycin-treated cells, we found no decrease in the
steady-state levels of let-7 and miR-21, two abundant miR-
NAs in HeLa cells, up to and beyond 24 h after treatment
(Figure 2B and Supplementary Figure 2, B and C), despite
Ago2 and GW182 protein levels significantly decreasing by
16 h after treatment (Figure 2A, Supplementary Figure 2A).
Next we investigated whether these miRNAs remained
functional in the presence of geldanamycin. Mock and
geldanamycin (10 M for 16 h) pretreated HeLa cells were
cotransfected with luciferase reporters that are regulated by
endogenous let-7. One miRNA sensor contained eight let-7 sites
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Figure 2. Geldanamycin treatment does not alter miRNA
level and miRNA function in human cells. (A) Geldanamycin
decreases Ago2 and GW182 levels after 8 h treatment. HeLa
cells were treated with DMSO or with geldanamycin (10M)
for the indicated times. The protein level of endogenous
hAgo2 and GW182 were followed by Western blotting.-Ac-
tin was used as loading control for Western blotting. (B)
miRNA level is unaltered after up to 24 h of geldanamycin
treatment. HeLa cells were treated with DMSO or geldana-
mycin (10 M) for the indicated times shown in A. The
relative let-7 level between the DMSO and geldanamycin-
treated cells was calculated at each time point using U6 as a
loading control. The graph shows the mean of three indepen-
dent experiments; error bars, SE. (C) Inhibition of HSP90
activity does not impair miRNA functions. HeLa cells were
pretreated with geldanamycin (10 M for 16 h) and trans-
fected with luciferase reporters that measure translational
repression and RNAi-mediated by endogenous let-7 (left
panel) and reporters that contain 3UTRs of known let-7–
targeted mRNAs (right panel). The dual luciferase data ob-
tained from the geldanamycin-treated cells (GD) were nor-
malized to the luciferase reading of the mock-treated cells
(M). Error bars, SE of three experiments. Left, no let-7,
Renilla luciferase containing no let-7 sites; let-7X8, Renilla
luciferase containing eight let-7 sites that mediate transla-
tional repression; let-7X3, Renilla luciferase contains three
perfect complementary let-7a sites; and let-7X3m, similar to
let-7X3 but carrying three point mutations in the let-7a seeds
and one at the cleavage sites. Right, nRAS, Firefly luciferase
carrying the 3UTR of nRAS; kRAS, Firefly luciferase carry-
ing the 3UTR of kRAS. (D) HSP90 association with com-
plexes containing mature miRNAs is not stoichiometric. Af-
finity purification was carried out with control (c) and
2-O-methyl oligo complementary to human let-7a (let-7) in
T-Rex cells inducible expressing FLAG::Ago2. The bound
fractions were assayed for the presence of FLAG::Ago2,
hAgo2, and HSP90 with Western blotting (left panel); 10% of
total lysate was loaded and half of the bound fraction. FLAG
IP was carried out in the same lysate using identical condi-
tions. The bound fraction was assayed for FLAG::Ago2, and
HSP90 with Western blotting (right panel). Empty bead (e)
was used as a negative control in the IP experiment. Ten
percent of the total lysate was loaded, and half of the IP for
the HSP90 panel and 10% of the total IP for the Flag::Ago2
panel was loaded.
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in the 3UTR that regulate the reporter expression through
miRNA-mediated translational repression (Iwasaki et al., 2009).
The second construct contained three perfect complementary
sites to let-7a; thus it is regulated by sequence-specific RNA
cleavage by endogenous let-7 miRNAs. Because the construct
containing three perfect complementary sites could be deemed
a strong repressor, we also used a third reporter construct
containing only one perfect complementary site to let-7a. For
controls we used similar reporters that contained either no let-7
target sites, or the let-7 target sites were mutated to make it
insensitive to let-7. We have also used previously published
reporters that contain the 3UTRs of nRAS and kRAS, which
have been shown to be regulated by let-7 in human cells
(Johnson et al., 2005). Figure 2C and Supplementary Figure 3A
show that geldanamycin treatment had no effect on the expres-
sion of the reporter plasmids. Endogenous let-7 was able to
regulate through translational repression as well as RNA in-
terference (RNAi) despite the significant loss of endogenous
Ago2 in the geldanamycin-treated cells (Supplementary Figure
3, B and C). In addition, we observed a remarkable drop rather
than increase in the endogenous RAS protein level in the
geldanamycin-treated cells (Figure 1C), the opposite effect of
that which would be expected if miRNA regulation had been
impaired. These results suggest that HSP90 inhibition has no
effect on the activity of the functional miRISC.
Having established that HSP90 activity is not required for
the activity of endogenous miRNA, we tested if HSP90
associates with Argonautes bound to miRNAs. For this, we
used a biotinylated let-7 complementary 2-O-methyl oligo that
was shown to effectively inhibit miRNA-programmed RISCs in
vitro and in vivo and is able to pull down proteins that asso-
ciate with single-stranded miRNAs (Hutvagner et al., 2004;
Meister et al., 2004; Robb and Rana, 2007). Using this ap-
proach, we showed that HSP90 was absent from the bound
fraction of the affinity purification carried out with the bio-
tinylated let-7 complementary 2-O-methyl oligo in spite of
the fact that Ago2 and transfected FLAG::Ago2 was retained
(Figure 2D and Supplementary Figure 3D). This is unlikely to
be a result of the conditions of the pull down because using an
identical experimental set up, we could successfully coimmu-
noprecipitate HSP90 with overexpressed FLAG::Ago2 (Figure
2D). This suggests that HSP90 does not bind Argonaute com-
plexes that contain unwound miRNAs stoichiometrically;
therefore, HSP90 probably functions upstream from RISC ac-
tion.
HSP90 Inhibition Affects miRNA Loading
Because geldanamycin has no affect on RISC function, we
tested if it influences small RNA loading. It has already been
published that geldanamycin prevents the direct binding of
Dicer to Argonaute in vitro and was suggested to disrupt the
RISC loading complex (RLC) formation in human cells (Tahbaz
et al., 2004). Very recently, it has been suggested that the mech-
anism responsible for small RNA loading in human cells is
analogous to fly Ago1, which does not require the RLC (Yoda
et al., 2010). In spite of this, we have tested if geldanamycin
affects the interaction of Dicer and Ago2 in vivo. We immuno-
precipitated endogenous Ago2 from mock- and geldanamycin-
treated cells and assayed the level of endogenous Dicer that
coimmunoprecipitated (Figure 3A and Supplementary Figure
4A). Dicer levels were comparable in the bound fraction of both
Ago2 immunoprecipitates, despite the lower levels of Ago2
detected in geldanamycin cells.
Next we tested if the loading of exogenous small RNA is
affected by HSP90 inhibition. Mock-treated and geldanamy-
cin-pretreated HeLa cells were transfected with increasing
amounts of firefly luciferase siRNAs and plasmids express-
ing firefly and renilla luciferases. Figure 3, B and C, and
Supplementary Figure 4, B–D, show that geldanamycin
treatment significantly reduced the level of endogenous
Ago2 and the efficacy of the luciferase siRNA by decreasing
the IC50 value three- to sevenfold.
Unloaded Argonautes Are Sensitive to Geldanamycin
Our previous experiment suggests that the inhibition of
HSP90 impairs siRNA function in mammalian cells; how-
ever, this experiment cannot distinguish between either the
impairment of siRNA loading or the activity of siRNA pro-
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Figure 3. Inhibition of HSP90 does not affect Argonaute–Dicer
interaction but impairs siRNA efficiency (A) Geldanamycin treat-
ment does not change the amount of Dicer associated with hAgo2.
hAgo2 was immunoprecipitated from mock- and geldanamycin-
treated (10 M for 16 h) Hela cells, and the bound fractions were
assayed for the presence of hAgo2 and Dicer with Western blotting.
Sup, supernatant. Ten percent of the total lysate and 25% of the total
IP were loaded. A longer exposure of the Dicer Western blot is
presented to show input Dicer levels. (B and C) Geldanamycin
treatment decreases siRNA efficiency. Mock- and geldanamycin-
treated (10 M for 16 h) HeLa cells were cotransfected with renilla
and firefly luciferase plasmids and with increasing concentrations of
siRNA targeting the firefly luciferase. Dual luciferase data at each
concentration were normalized to data obtained with a nontarget-
ing siRNA (10 nM) and fitted to a sigmoid curve using a Hill
coefficient of 1. The concentration of siRNA required for half-max-
imal inhibition (IC50) was calculated and separately plotted (C).
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grammed RISC. However, we already have shown that
geldanamycin does not influence endogenous RISC activity;
therefore, we hypothesized that HSP90 activity is required
for the stability of RNA-free Argonautes. If HSP90 activity is
required to stabilize RNA-free Argonautes, then preloading
siRNA into Argonautes should alleviate geldanamycin inhi-
bition. We transfected increasing amounts of luciferase
siRNA into HeLa cells with and without providing the cog-
nate target luciferase expression plasmid and then subse-
quently treated the cells with geldanamycin. We observed
that transfection of increasing amounts of siRNA prevented
geldanamycin having an effect on Ago2 levels (Figure 4A).
The increased stability of Ago2 was concentration depen-
dent but the presence or absence of the target mRNA had no
effect (Figure 4B). We also predicted that Ago2 that is im-
paired in small RNA binding would be more sensitive to
geldanamycin treatment than wild-type Ago2. To test this
we used a characterized Ago2 mutant containing 10 muta-
tions in the PAZ domain that was shown to bind small
RNAs less effectively (Liu et al., 2005b). Figure 4C shows that
the transiently expressed PAZ mutant Ago2 was more sen-
sitive to geldanamycin treatment than the wild-type Ago2
construct. Next, we repeated this experiment while cotrans-
fecting 10 nM of a nontargetting siRNA together with the
FLAG-tagged Ago plasmids. As Figure 4D shows, the co-
transfected siRNA has a more pronounced effect, alleviating
the effects of HSP90 inhibition on wild-type Ago2 but not the
PAZ mutant. These data together strengthen our hypothesis
that HSP90 is mainly required for the stability of unloaded
Argonautes; however, we cannot rule out the possibility that
the conformational changes that may be introduced by the
mutations influence the stability of the Ago2 PAZ mutant.
DISCUSSION
HSP90 together with other cochaperones are the major com-
ponent of the proteome that copurifies with Argonaute and
Piwi proteins (Hock et al., 2007; Landthaler et al., 2008; Vagin
et al., 2009). Here we have shown that the inhibition of
HSP90 activity by well-described inhibitors such as geldana-
mycin and 17AAG resulted in the decrease of microscopic
P-bodies and the destabilization of key components of the
miRNA-mediated regulatory pathway such as Argonautes
and GW182 proteins. While we were revising this manu-
script, the destabilization of human Ago2 by the inhibition
of HSP90 has been independently reported (Suzuki et al.,
2009). We identified that HSP90 inhibition reduces siRNA
efficacy, and we are proposing that HSP90 is required for the
stabilization of RNA free Argonautes.
Originally HSP90 function was suggested to stabilize the
interaction between Dicer and human Ago2, implicating it in
the facilitation of loading of miRNAs to RISC (Tahbaz et al.,
2004). This role of HSP90 has been recently challenged, and
it was suggested that HSP90 modulates Argonaute function
at the effector step of miRNA-mediated gene regulation and
miRNA-mediated sequence-specific cleavage (Pare et al.,
2009). Our finding is partially consistent with the latest
reports because we also have found that geldanamycin does
not disrupt the interaction between Dicer and Ago2 in vivo.
We also confirmed that geldanamycin treatment either abol-
ishes or reduces the size of microscopic P-bodies (Pare et al.,
2009; Suzuki et al., 2009). However, Pare and colleagues have
found that inhibition of HSP90 activity impairs both miRNA
function in translational repression and sequence specific RNA
cleavage. In contrast, we presented several lines of evidence
that show that HSP90 is not required for miRNA-mediated
gene repression and RNAi at the regulatory step in human
cells. First, we have shown that mature miRNA levels were not
affected and that HSP90 is not a stoichiometric component of
the human RISC. Second, we have explicitly demonstrated,
using five let-7 regulated reporters, that HSP90 activity did not
impair the activity of endogenous let-7 even though Ago2
levels were significantly decreased upon HSP90 inhibition.
Furthermore, the expression of an endogenous let-7 target, Ras,
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Figure 4. HSP90 stabilizes unloaded Argonautes. (A
and B) Increasing the level of loaded hAgo2 makes it
more resistant to geldanamycin treatment. HeLa cells
were transfected with increasing amount of siRNA tar-
geting the Firefly luciferase without (A) and with (B) the
cognate target plasmid followed by treatment of either
DMSO or geldanamycin (10 M for 16 h). The level of
endogenous hAgo2 was assayed with Western blotting.
-Actin was used as a loading control. (C and D) Argo-
naute that is impaired in small RNA binding is more
sensitive to HSP90 inhibition. (C) HeLa cells were tran-
siently transfected (24 h) with FLAG-tagged hAgo2
(FLAG:Ago2) or FLAG-tagged hAgo2 with a series of
mutations within its PAZ domain (FLAG:Ago2PAZ10)
and were subsequently treated with either DMSO or
geldanamycin (10 M for 16 h). Expressions of the over-
expressed plasmids and endogenous hAgo2 were as-
sayed with Western blotting. -Actin was used as a
loading control. (D) A similar experiment to that des-
ribed in C, only the FLAG-tagged Ago2s were cotrans-
fected with 10 nM nontargeting siRNA.
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declined rather than increased after geldanamycin treatment,
suggesting that let-7 function was not altered by the drug. This
is consistent with previous findings that Ras directly interacts
with Raf and upon HSP 90 inhibition the interaction dissociates
and Raf is degraded (Schulte et al., 1995).
Our data suggest that HSP90 activity is required for the
stability of Ago2 when it is not loaded with small RNA. We
have shown that HSP90 was not associated with Ago2 when
it was affinity purified with the let-7 complementary biotin-
ylated 2-O-methyl oligo. We then identified that Ago2 sen-
sitivity to geldanamycin could be attenuated by the trans-
fection of siRNA into the cells, presumably by generating
excess siRNA-associated Argonautes. Finally, we demon-
strated that Ago2 defective in small RNA binding was more
sensitive to HSP90 inhibition. In our interpretation, the in vitro
experiment conducted by Pare et al. (2009) in fly ovary lysates
also supports our findings that HSP90 inhibition impairs small
RNA loading, because they have shown that geldanamycin-
treated lysate could be poorly programmed with exogenously
siRNAs to cleave the complementary target.
The simplest hypothesis for the role of HSP90 in miRNA-
mediated gene regulation is that HSP90 chaperones RNA-
free Argonautes, allowing them to adopt a conformation
that facilitates efficient loading of an RNA substrate. After
Argonaute binds to the RNA substrate, HSP90 dissociates.
This may be analogous to the role that HSP90 has in stabi-
lizing steroid receptors with an exposed hydrophobic cleft to
facilitate ligand binding (Pratt et al., 2008). Indeed, structural
and biochemical studies of the PAZ domain of Argonautes
showed that it binds to the 3 overhang of a RNA molecule
with a fairly closed hydrophobic binding pocket (Lingel et
al., 2003, 2004; Song et al., 2003; Yan et al., 2003). This inter-
action was shown to be relatively weak in vitro, suggesting
that it may need such a chaperone to be effective in binding
in vivo (Lingel et al., 2003).
Interestingly, while we were revising this manuscript, a
study proposed that small RNAs in human cells do not form
the canonical RLCs that has been described to be necessary
for loading Drosophila Ago2. It is suggested that loading of
human Argonautes is analogous to Drosophila Ago1 where
loading is uncoupled from Dicer (Yoda et al., 2010). Also, it
was shown that the loading of small RNAs in human cells is
stimulated by ATP (Yoda et al., 2010). Our findings may
suggest that small RNAs are directly loaded into Argo-
nautes, and the ATP dependence of this loading event may
reflect the chaperoning activity of HSP90, which protects
unloaded Argonautes from degradation by the proteosome.
We have also shown that inhibition of HSP90 reduced the
number of microscopic P-bodies. This is probably a conse-
quence of the destabilization of the GW182 protein family, a
key component of the P-bodies, rather than Ago2 because
the presence of Ago2 is not required to form this cytoplasmic
structure (Lian et al., 2007; Jagannath and Wood, 2009). Also,
when we rescued Ago2 from HSP90 inhibition by transfect-
ing increasing amounts of siRNA into the cells before
geldanamycin treatment (Figure 4A), we did not observe a
significant increase in the number or size of P-bodies in the
geldanamycin-treated cells (Supplementary Figure 5, A and
B), suggesting that the depletion of P-bodies is independent
of the effect of HSP90 on Argonautes. Interestingly, the
almost total depletion of such cytoplasmic foci did not result
in impairment of miRNA-mediated gene regulation, sup-
porting the recent hypothesis that visible P-body formation
is not a prerequisite for normal function of miRNAs (Eulalio
et al., 2009). The drastic drop in the number of visible P-
bodies also coincides with a marked decrease of Argonautes
and GW182 proteins, two key proteins in miRNA-mediated
gene regulation, without any detectable defect in the func-
tion of endogenous miRNAs. This may be because the bulk
of P-bodies contain GW182 proteins that are not active in
miRNA-mediated gene regulation.
In our studies we applied geldanamycin for a limited time,
usually up to 16 h, which caused an alteration in the protein
levels of Argonaute and GW182. In this timescale we observed
a significant reduction of exogenous siRNA efficacy without
the impairment of endogenous miRNA functions. Our findings
also suggest that endogenous miRNA complexes are very sta-
ble with a turnover exceeding 16 h. However, longer exposure
of geldanamycin resulted in a decline of endogenous miRNA
levels (Figure 2B and Supplementary Figure 2B), suggesting
that in the long-term, HSP90 inactivation would inhibit
miRNA-mediated gene repression by preventing loading of
miRNAs because of the loss of Argonautes.
The antitumor effects of HSP90 inhibitors have been quite
astounding: geldanamycin analogues that are currently in
clinical trials have been shown to slow tumor growth by 50%
(Goetz et al., 2003). HSP90 inhibitors potentially benefit, by
inhibiting the functions of overexpressed miRNAs that pro-
mote oncogenesis (Sotiropoulou et al., 2009). It would be
interesting to see how such treatments influence miRNA-
mediated gene regulation in tumors.
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